Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.57 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8808194 | 0.86 | AR (0.53) | MAOBARMAOA | |
| SCHEMBL4339811 | 0.84 | MAOB (0.62) | MAOBPARP10MAOANR4A2 | |
| SCHEMBL5090273 | 0.82 | MAOB (0.66) | MAOBAPPCA12CA1CA2 | |
| SCHEMBL3505720 | 0.81 | MAOB (0.64) | MAOBAPPCA12CA1CA2 | |
| SCHEMBL21332700 | 0.79 | SCN9A (0.47) | AR | |
| SCHEMBL7260487 | 0.79 | AR (0.62) | MAOBAR | |
| SCHEMBL14619058 | 0.78 | MAOB (0.51) | MAOBAPPNR4A2 | |
| SCHEMBL4324579 | 0.78 | MAOB (0.60) | MAOBAPPCA12CA1CA2 | |
| SCHEMBL1582627 | 0.76 | AR (0.53) | MAOBARAPPCA12CA1 | |
| SCHEMBL4334933 | 0.76 | MAOB (0.65) | MAOBARMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492588-B2 | Benzyloxy anilide derivatives useful as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120329869-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL | 2012-12-27 | — | — | US | disclosed |
| US-8188314-B2 | Benzyloxy anilide derivatives useful as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090326059-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329869-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | KCND2, KCNB2, KCNAB1 | MAOB 549/4885AR 3633/4885APP 909/4885 |
| US-20090326059-A1 | BENZYLOXY ANILIDE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | KCND2, KCNB2, KCNAB1 | MAOB 549/4885AR 3633/4885APP 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.